16 cancers, including Lung cancer, breast cancer, colorectal cancer, liver cancer, esophageal cancer, stomach cancer, pancreatic cancer, ovarian cancer, cervical cancer, nasopharyngeal cancer, endometrial cancer, gallbladder cancer, lymphoma, prostate cancer, bladder cancer and kidney cancer.
Conditions
Interventions
Lung cancer:NA
Esophageal cancer:NA
Stomach cancer:NA
Cervical cancer:NA
Endometrial cancer:NA
Gallbladder cancer:NA
Prostate cancer:NA
Kidney cancer:NA
Ovarian cancer:NA
Nasopharyngeal cancer:NA
Lymphoma:NA
Bladder cancer:NA
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
40 Years to 74 Years
Inclusion criteria
Inclusion criteria: 1: Pathologically diagnosed as any one of 16 types of cancer, including Lung cancer, breast cancer, colorectal cancer, liver cancer, esophageal cancer, stomach cancer, pancreatic cancer, ovarian cancer, cervical cancer, nasopharyngeal cancer, endometrial cancer, gallbladder cancer, lymphoma, prostate cancer, bladder cancer and kidney cancer. 2: Age eligible for the study: 40=age<75 3: Did not received any systemic or local anti-tumor treatment before screening, including but not limited to surgical resection, radiotherapy and chemotherapy, endocrine therapy, targeted therapy, immunotherapy, cell therapy, interventional therapy, etc. 4: Able to sign informed consent, and be willing to comply with sample collection, assessment and follow up of this study.
Exclusion criteria
Exclusion criteria: 1: Female patients who are pregnant, lactating; 2: Patients with a known malignancy or history of malignancy; 3: Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of = 38.5 °C) within 14 days prior to screening; 4: Taken any of the following medications within 14 days before screening: Intravenous or oral use of glucocorticoids, azacitidine, decitabine, procainamine, hydrazine Hydrazine, arsenic trioxide; 5: Received organ transplant, bone marrow transplant, stem cell transplant before screening, or received blood transfusion within 30 days prior to screening; 6: Other situations not suitable for enrollment determined by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Limit of Detection;Accuracy; | — |
Countries
China
Contacts
Public ContactYu Xianjun
Fudan University Shanghai Cancer Center
Outcome results
None listed